RxDoctor Payments Data

Razvan Tornea, MD

Child & Adolescent Psychiatry · Southampton, PANPI 1497866164

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.4% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 38.0% of the total. 2025 is the largest year on record at $313, 5.0 times the $63 reported in 2019.

$816in general payments, 2019–2025

Across 54 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$310
  • AbbVie$198
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$173
  • Idorsia Pharmaceuticals US Inc$23
  • Bausch Health US, LLC$22
  • Corium, LLC$19
  • plus $70 from 5 others

What the payments were for

  • Food & beverage$73790%
  • Education$7810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$816 in reported general payments places this provider in the 70th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

See all child & adolescent psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$17,106
Medicare patients
39
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate12$19,480
Seroquel XrQuetiapine Fumarate48$18,538
LatudaLurasidone Hcl13$16,311
RexultiBrexpiprazole11$15,912
Effexor XrVenlafaxine Hcl13$14,347
Aripiprazole132$11,377
Lurasidone Hcl12$9,117
Lamotrigine ErLamotrigine12$5,222
Fluvoxamine Maleate ErFluvoxamine Maleate13$4,735
Olanzapine45$2,850
Methylphenidate ErMethylphenidate Hcl13$2,086
Guanfacine Hcl ErGuanfacine Hcl17$2,008
Quetiapine Fumarate ErQuetiapine Fumarate14$1,889
Divalproex Sodium ErDivalproex Sodium44$1,848
Oxcarbazepine26$1,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$173$19,48012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

Other child & adolescent psychiatry in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →